Human CMV infects between 50-85% of healthy individuals and can cause live-threatening infections in immunocompromised patients. Therefore, peptide vaccination is being developed as a promising immunotherapeutic approach for treatment of patients at risk of CMV disease. The enzymatically inactive toxoid of Bordetella adenylate cyclase (CyaA-AC À ) was shown to be an efficient tool for delivery of peptide epitopes and stimulation of Ag-specific T-cell immune responses. We investigated here the capacity of two CyaA-AC À constructs to deliver epitopes derived from the CMV phosphoprotein pp65 for activation of human T cells in vitro. Expansion of c-IFN-secreting CMV-specific CD8 þ T cells, as well as increase of total IFN-c and TNF-a production by PBMCs from CMV-seropositive donors were observed after in vitro stimulation with CyaA-AC À constructs carrying CMV epitopes, whereas limited activation of immune response occurred with free peptides. The activation of immune response was confirmed by expansion of CMV-specific T-cell clones and anti-CMV cytotoxic effect of stimulated PBMCs. These data open the way to clinical evaluation of CyaA-AC À constructs as tools for detection and expansion of CMV-specific T-cell immune responses for diagnostic and immunotherapeutic applications against CMV-associated diseases.
Introduction
CMV is an opportunistic pathogen in humans that can cause disease after both primary and recurrent infections. 1 Although infection with CMV generally provokes no or minor symptoms in immunocompetent individuals, it causes serious complications leading to life-threatening infections in patients with defects in cellular immunity. CMV infection is controlled by specific CD8 þ cytotoxic (CTL) and CD4
þ T helper cells. 2 Therefore immunocompromised recipients of allogeneic hematopoietic stem cells or solid organ transplants and HIV positive patients are the most vulnerable to severe CMV disease. [3] [4] [5] Pregnant women represent another risk group that may transmit the virus to their offsprings with a high risk of mental retardation and sensorineural deafness as a direct consequence of CMV infection. 6 Therefore, it is important to develop strategies for either ex vivo or in vivo activation and expansion of CMV-specific T-cell clones that could be used for the treatment of CMV-disease in immunocompromised patients. Although the first attenuated Towne vaccine against CMV was developed 3 decades ago, 7, 8 at doses tested to date it has failed to stop CMV acquisition in CMV-seronegative healthy individuals or transplant recipients. [9] [10] [11] [12] Various experimental vaccines, including DNA or recombinant CMV glycoprotein vaccines and vaccines based on CMV-specific Ag expression by non-replicating (viral) carriers, have been evaluated in animal models, as well as in clinical trials. [13] [14] [15] [16] [17] Vaccines based on immunogenic peptides represent another approach for the induction of strong and CMV-specific T-cell responses. Recently, a CD8 þ T-cell-specific antigenic peptide 495-503 derived from CMV capside phosphoprotein pp65 has been used for the preparation of anti-CMV vaccine for immunocompromised leukemia and lymphoma patients who underwent allo SCT. 18 Vaccination with CMV peptide-loaded DCs was also shown to potently activate CMV-specific T cells in patients after allo SCT. 19 Furthermore, adoptive transfer of donor-derived CMV-specific T cells, selected by the reactivity to antigenic peptides, may represent another way of conferring a long-lasting protection from CMV disease. First promising results have been, indeed, documented in patients after allogeneic stem cell or solid organ transplantation. 20, 21 Recently, enzymatically inactive (genetically detoxified) recombinant form of the cell-invasive adenylate cyclase toxin of Bordetella pertussis (CyaA-AC À ) has been established as an excellent tool for delivery of peptide Ags into the cytosol of APCs. CyaA-AC À was shown to target APCs using their CD11b/CD18 receptor and to translocate its N-terminal adenylate cyclase domain with inserted T-cell epitopes into cell cytosol. Subsequently, the toxoid is processed and epitopes are presented in association with MHC class I molecules to specific CD8 þ T cells both in vitro and in vivo. [22] [23] [24] Moreover, subsequent endocytosis of the toxoid with the CD11b/CD18 integrin receptor ensures also the delivery and presentation of MHC-class II-restricted epitopes to CD4 þ T cells. 25, 26 A number of studies have demonstrated the efficacy of CyaA-AC À in Ag delivery for activation of specific protective and immunotherapeutic T-cell immune responses. [27] [28] [29] [30] At present, the first cGMP grade CyaA-AC À carrying tumor epitopes have been released for a phase I/II clinical trials aiming at immunotherapy of metastatic melanoma (P Sebo, personal communication).
Here, we inserted two different combinations of CMV-specific epitopes derived from CMV phosphoprotein pp65 into CyaA-AC À toxoids and examined their potential to stimulate human cellular immunity in vitro.
Materials and methods

Samples from healthy donors
The blood donors signed an informed consent approved by the local ethical committee of the University hospital Brno. PBMCs from 10 CMV-seronegative (without detectable level of anti-CMV IgM and IgG antibodies in serum) and eight CMV-seropositive donors (anti-CMV IgG antibodies detectable in serum) were used. All healthy donors were positive for human leukocyte Ag A*0201 (HLA-A*0201) and were recruited from healthy blood donors at the Transfusion unit. PBMCs were isolated by Histopaque (Sigma-Aldrich, Prague, Czech Republic) gradient centrifugation of anticoagulated blood buffy coats. Viable cells were quantified and cryopreserved in Hanks' BSS containing 40% fetal bovine serum and 10% DMSO (all Sigma-Aldrich) and stored in liquid nitrogen.
Construction and purification of recombinant adenylate cyclase CyaA-AC À toxoids carrying CMV epitopes The CyaA-AC À carriers for CMV epitope delivery were constructed on the backbone of the adenylate cyclase toxoid CyaA/108OVA/AC À . 31 This toxoid was devoid of adenylate cyclase activity due to the insertion of a GlyPhe dipeptide into the ATP binding site of the AC domain. 24 Concomitantly, between residues 107 and 108 this toxoid also carried a CD8 þ T cell epitope SIINFEKL tag (residues 257-264 of chicken ovalbumin). Synthetic minigenes, which encoded selected epitopes from pp65 phosphoprotein of human CMV strain AD169 with documented potency to activate immune response (G2 and G3, Table 1 ), were purchased from GeneArt (Regensburg, Germany) and inserted between codons 233 and 234 of the cyaA gene into the unique restriction site BrgGI of the plasmid pT7CT7ACT1 (Sadilkova et al., unpublished). The constructs were verified by DNA sequencing. The recombinant CyaA-G2-AC À (carrying HLA-A2 and B7-restricted CD8 þ CMV epitopes) and CyaA-G3-AC À (carrying HLA-A2 CD8
þ CMV epitope and HLA-DRB1, DR3, DR11 CD4 þ CMV epitopes) toxoids were produced in E. coli BL21/pMM100 (lac repressor gene lacl q encoded by pMM100 plasmid) in the presence of the activating protein CyaC. Toxoids were purified as described previously. 31 Bacterial endotoxin was removed by repeated washing of the phenyl sepharose resin with bound toxoids during hydrophobic chromatography by several volumes of 60% isopropanol. 32 In the final step, CyaA proteins were eluted with 8 M urea, 2 mM EDTA, 50 mM Tris-HCl, pH 8.0, and stored at À20 1C. The endotoxin content in the samples was determined by LAL assay (QCL-1000; Cambrex, East Rutherford, NJ, USA) and was below 0.024 EU/mg of purified protein. Before the assay, the CyaA toxoids were pre-diluted 50 mM Tris-HCl, pH 8. À toxoid without CMV epitopes) to deliver epitopes into APC's cytosol for processing and MHC class Irestricted presentation was verified using an in vitro assay for presentation of the ovalbumin epitope SIINFEKL by murine primary DCs to OVA-specific CD8 þ T-cell line B3Z. 33 
Synthetic peptides
All peptides synthesized by ProImmune Limited (Oxford, UK) were of at least 98% purity, as confirmed by the HPLC. CMV antigenic peptides used for this study were derived from CMV phosphoprotein pp65. Peptide A (495-503), NLVPMVATV, corresponded to an HLA-A* 0201-restricted CD8 þ T-cell epitope. Peptide B (417-426), Table 1 CyaA toxoids with inserted pp65 epitopes used in this study ) from all donors were incubated with indicated Ags in a high glucose DME medium with L-glutamine (Lonza, Verviers, Belgium), 8% male human AB þ serum and 1% penicillin-streptomycin (both SigmaAldrich) at cell concentration 2 Â 10 6 per mL. For optimal stimulatory capacity, 5 nM (0.9 mg/mL) concentration of CyaA-G2-AC À and CyaA-G3-AC À , or of the control mock toxoid (CyaA/108OVA/AC À ), was used, as increased toxoid molarity did not significantly enhance the immunostimulatory capacity (data not shown). Final urea concentration was kept below 0.08 mM in all assays and it had no effect on the cell physiology whatsoever. For comparison, a final concentration of 5 nM of CMV peptides (A to D) was used.
T lymphocyte activation was measured by flow cytometry. The IFN-g secretion assay was used to detect produced IFN-g captured on cell surface (Miltenyi Biotec, Bergisch Gladbach, Germany). Cytometric bead array was used to detect IFN-g and TNF-a production in the cultivation medium. T-cell activation was detected by both experimental methods after 6 and 18 h of cultivation in 5% CO 2 atmosphere at 37 1C.
Cell line T2 cells (ATCC-number: CRL-1992) were cultured in a standard DME medium with L-glutamine (Lonza) with 10% bovine fetal serum and 1% penicillin-streptomycin (both Sigma-Aldrich).
Cytokine secretion assay PBMCs were incubated with the IFN-g Catch Reagent according to manufacturer's instructions (Miltenyi Biotec). PBMCs were resuspended in 80 mL of phosphate buffered saline (PBS) containing 2% of human albumin (Grifols, Barcelona, Spain) and incubated with anti-CD3 labeled with PeCy7 (Immunotech, Marseille, France), anti-CD8 labeled with FITC (EXBIO, Prague, Czech Republic), anti-CD4 labeled with PerCP-Cy5.5 (BD Biosciences, San Jose, CA, USA) and anti-human IFN-g labeled with PE (Miltenyi Biotec) monoclonal antibodies for 15 min at room temperature. Cells were washed with 2.5 mL of PBS and resuspended in 200 mL of PBS. The percentage of IFN-g positive CD8 þ T cells was determined using flow cytometry. Cytotoxicity test T2 line cells were labeled with 1 mM carboxy-fluorescein diacetate, succinimidyl ester (Sigma-Aldrich) for 10 min at 37 1C. Labeling was stopped by addition of male human AB þ serum (Sigma-Aldrich), the cells were washed twice and resuspended in DME medium with 2% male human AB þ serum. Prior to use, the T2 cells were loaded with 10 mg/mL of A0201 NLVPMVATV peptide for 2 h, or left non-loaded. PBMCs were subjected to antigenic stimulation with the indicated CyaA-AC À toxoids for 7 days and then mixed with carboxy-fluorescein diacetate, succinimidyl ester-labeled T2 cells, at an effector to target ratio of 1:1, 5:1 and 10:1, respectively. After 3 h of coincubation, cells were stained with propidium iodide (1 mg/mL; Sigma-Aldrich) and the percentage of dead PI þ CFSE 
Statistical analysis
The data were analyzed by STATISTICA 8 (StatSoft, Prague, Czech Republic). Mann-Whitney test was used for comparison of two groups. Kruskal-Wallis test was used for comparison of three and more groups. Experimental data were compared with corresponding controls, and a P value of 0.05 or less was considered significant.
Results and discussion
First the capacity of CyaA-G2-AC À and CyaA-G3-AC À toxoids to deliver CMV phosphoprotein pp65 epitopes into APCs and to stimulate CMV-specific CD8 þ T-cell
CyaA-AC À activates T cell by pp65 epitope J Jelinek et al responses in vitro was examined. Furthermore, the stimulatory capacity of CyaA-G2-AC À and CyaA-G3-AC À toxoids was compared with the stimulatory capacity of corresponding antigenic peptides alone.
As documented in Figure 1 , incubation of PBMCs from CMV-seropositive healthy donors for 6 h with both CyaA-G2-AC À and CyaA-G3-AC À toxoids resulted in a significant increase in percentage of CD8 þ T cells secreting þ T cells was determined by flow cytometry after 6 h (a, b) and 18 h (c, d) of incubation. The total production of IFN-g (e, f) and TNF-a (g, h) in the culture media was determined by cytometric bead array after 18 h of incubation. Figures 1a and b) , as compared with control nonstimulated PBMCs or PBMCs incubated with the mock CyaA-AC À toxoid devoid of CMV peptide epitopes. Comparable CD8 þ T-cell activation, without further enhancement, was detected after 18 h of cultivation with both CyaA-G2-AC À and CyaA-G3-AC À toxoids in six from eight donors (Figures 1c and d) .
IFN-g (
Next, we examined the immunodiagnostic and immunostimulatory potential of CyaA-G2-AC À and CyaA-G3-AC À toxoids by assessing their capacity to stimulate the overall IFN-g and TNF-a production in PBMCs culture. As shown in Figures 1e and f, compared with non-stimulated PBMCs or PBMCs incubated with mock CyaA-AC À , a statistically significant increase of total amounts of secreted IFN-g and TNF-a was observed upon 18 h of incubation of PBMCs from CMV-seropositive healthy donors with both CyaA-G2-AC À and CyaA-G3-AC À toxoids. Importantly, no activation of PBMCs from CMV-seronegative donors incubated with CyaA-G2-AC À and CyaA-G3-AC À was detected (Figures 2a and b) . Moreover, as documented in Figure 3 , by comparison to non-stimulated PBMCs or PBMCs incubated with the mock CyaA-AC À toxoid, the incubation of PBMCs from CMV-seropositive donors for 5 days with CyaA-G2-AC À and CyaA-G3-AC À toxoids induced a statistically significant expansion of CD8 þ T lymphocytes specific for the pentamer loaded with the HLA-A*0201 495-503 peptide epitope (NLVPMVATV). Furthermore, the activated T lymphocytes exhibited a specific cytotoxic activity and permeabilized T2 target cells pulsed with the HLA-A*0201 495-503 peptide (NLVPMVATV), as shown in Figure 4 . In contrast, no epitope-specific cytoxic activity was associated with non-stimulated PBMCs or PBMCs incubated with the mock CyaA-AC À toxoid. Importantly, the CyaA-G2-AC À and CyaA-G3-AC À recombinant toxoids exhibited a significantly higher activation potential than the corresponding free CMV peptides at an equal molar concentration (5 nM). A significantly higher percentage of IFN-g-secreting CD8 þ T cells and higher total IFN-g and TNF-a production was induced upon stimulation with the CyaA-G2-AC À or CyaA-G3-AC À toxoids, as compared with incubation with free antigenic peptides (Figure 1 ). Pentamer staining also revealed a significantly stronger expansion of CD8 þ T cells specific for (Figure 3 ). In summary, the results show that delivery of the pp65 CD8 þ T cell epitopes by both recombinant toxoids, CyaA-G2-AC À and CyaA-G3-AC À , induced CMV-specific activation of CD8 þ T cells in PBMCs from CMV-seropositive healthy donors. Moreover, the activation of CD8 þ T cells was paralleled by a significant increase of IFN-g and TNF-a production from stimulated cells and followed by expansion of CMV-specific CD8 þ T cells. Importantly, both toxoids activated a CMV-specific immune response at a quite low molar concentration of 5 nM, at which only a minimal activation by free peptides could be observed. Indeed, free peptides are typically usually used for activation of CMV-specific CD8 þ T cell clones at a concentration of 1 mg/mL 38, 39 , which corresponds to three orders of magnitude higher molar concentration (B1 mM). In addition, the activation of CMV-specific CD8 þ T cells upon Ag delivery by CyaA toxoids was achieved without the need of costimulatory molecules, such as the addition of monoclonal antibodies against CD28 and CD49d that are used to maximize the detection of T cells with higher activation thresholds. 40 Our results are in line with the unique ability of the CyaA-AC À toxoid to specifically target the APCs expressing the CD11b/CD18 integrin and, to translocate into their cytosol the AC moiety containing the inserted epitopes, thereby enabling effective delivery of the CMV epitopes for processing and presentation. An additional advantage of CyaA-AC À toxoid as a carrier for CMV epitopes might lie also in its inherent adjuvant capacity. Recently, CyaA-AC À has been shown to induce K þ efflux from CD11b þ target cells 41 and to contribute to activation of inflammasome and IL-1b production in murine BM-derived DCs. 42, 43 Therefore it is tempting to speculate that besides delivering the Ags the CyaA-AC À toxoid might also act as an adjuvant and promote maturation of APCs via autocrine/paracrine production of IL-1b.
Recently, restoration of immune response against CMV using CMV-specific T cells has shown promise in treatment of CMV-associated disease in patients resistant to virostatic therapy. 38 The presented results here show that CyaA-AC À toxoids delivering inserted CMV epitopes can efficiently activate and expand human CMV-specific cytotoxic T-cells present in PBMC samples from healthy seropositive donors. This justifies future clinical evaluation of cGMP toxoid material in an adoptive immunotherapy trial in transplanted patients at risk of CMV disease. Further, the Ag delivery technology employing CyaA-AC À toxoids deserves evaluation as a potential diagnostic tool for detection of CMV-specific cellular immunity in graft material before transplantation.
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